New CRISPR Screening Service, Calla Lily Joins Wellcome Leap’s Program, Baylor College to Establish Xenoliver Transplant Center

Lonza announced its Rapid Media Prototyping Service (RaMP), giving biopharmaceutical companies faster access to custom liquid and powder media for screening, process confirmation and early development. RaMP is part of Lonza's end-to-end custom media and buffer solutions offering, supporting customers from media development and screening through non-GMP prototyping and commercial GMP manufacturing. By linking early formulation work with long-term scalability, the service helps simplify development and support manufacturing readiness. Press release. 

bit.bio announced the launch of the ioScreen platform, a new CRISPR screening service designed to accelerate human cell-based drug discovery. The ioScreen platform service enables scientists to switch genes on or off or modulate their activity to better understand disease biology. Powered by bit.bio's ioCells, as well as other cell types, the ioScreen platform combines industrial-scale CRISPR screening with billions of consistent, mature human iPSC-derived cells. Press release. 

RyboDyn released a preprint titled "Discovery and Targeting of a Cryptic Human Proteome", mapping an entire layer of human biology that the field has systematically missed and showing it is dense with the tumor-specific targets cancer drug developers have run short of. This cryptic human proteome comprises tens of thousands of peptides (the detectable fragments of the larger full-length cryptic proteins they come from) encoded by regions of the human transcriptome that reference annotations have never captured. Preprint. 

Calla Lily Clinical Care has joined Wellcome Leap’s Focused Antibiotics program, a new $50 million funded program to transform how antibiotics are delivered and address the growing global threat of antimicrobial resistance. The Focused Antibiotics program aims to leverage innovative technologies to address the unintended effects of antibiotic use, reformulating existing treatment options so that they reach the site of infection while sparing the gut microbiome without loss of efficacy. Press release. 

Elemental Machines announced the launch of Resources Manager, its asset intelligence platform that is designed to enable life sciences teams to move beyond simple asset monitoring and manage the operational context around their equipment, locations, schedules, and records. Through the intelligence platform, teams can organize equipment, sensors, and locations in a real-world hierarchy, from office parks and buildings down to rooms, benches, instruments, and connected devices. The platform supports both connected and unconnected equipment, enabling teams to manage the full lab environment whether an asset is actively monitored or simply tracked, scheduled, documented, and maintained. Press release. 

Broken String Biosciences launched BaseMap ABE. Built on the company's INDUCE-seq technology, BaseMap ABE extends the platform's capabilities to support adenine base editing (ABE) applications. Unlike prediction-based approaches, BaseMap ABE generates genome-wide data directly from biologically relevant cells, providing researchers with clear understanding of editor specificity under physiologically relevant conditions. The platform enables rapid, unbiased identification of off-target events while generating standardized and robust data to support guide optimization, editor selection, and preclinical decision making. Press release. 

Northwest Biotherapeutics has entered a non-binding Memorandum of Understanding (MOU) with the Saudi Pharmaceutical Industries and Medical Appliance Company (SPIMACO) for a collaboration to bring the company's DCVax-L products and technology to Saudi Arabia. The MOU establishes a general framework for discussions for the potential collaboration regarding the approval, commercialization, supply, and technology transfer of the company's DCVax-L product for glioblastoma brain cancer in Saudi Arabia. Over time, the collaboration may expand by mutual agreement to include DCVax-L products for other indications in addition to brain cancer, and may expand to include other territories, such as Gulf Cooperation Council countries. Press release. 

Evotec has entered a strategic R&D collaboration with Odyssey Therapeutics to discover potential new treatments in autoimmune and inflammatory diseases. Under the agreement, Odyssey will leverage Evotec's integrated data-driven discovery platform, advanced screening capabilities, and AI-enabled data science technologies to discover and validate differentiated small molecule drug candidates across multiple high-value disease targets. By combining high-throughput experimentation with machine learning-driven analysis, the collaboration is designed to accelerate the identification of validated hit series and enable the rapid progression of promising therapeutic programs with the potential to transform the standard of care. Press release. 

CREATE announced a strategic research collaboration with Australia's Monash University and its Monash Institute of Pharmaceutical Sciences. The partnership broadens CREATE's portfolio by accessing Monash's advanced lipid nanoparticle technology including proprietary binders and chemistry, strengthening its leadership in developing best-in-class targeted in vivo therapies. Targeted delivery remains one of the primary challenges in realizing the full therapeutic potential of in vivo cell therapies, requiring increasingly precise control over which immune cells receive therapeutic payloads. Press release. 

Clean Cells acquired Anaquant. Clean Cells takes entire ownership of Anaquant’s brand, intellectual property, proprietary mass spectrometry-based analytics platform, equipment and existing client relationships, strengthening Clean Cells’ capabilities in protein characterization, a critical requirement in biopharmaceutical quality control and regulatory readiness. Under the deal, Clean Cells also obtains Anaquant’s ReadyBeads technology, a proprietary reference standard product line for Host Cell Protein (HCP) profiling and targeted quantification of drug product specific HCPs. Press release. 

Schrödinger launched its early access version of Bunsen, its new agentic AI co-scientist that helps researchers understand scientific objectives, develop computational strategies, execute sophisticated molecular discovery workflows and interpret results. By combining AI with physics-based simulation, Bunsen allows researchers to evaluate more hypotheses, explore chemical space more efficiently, and make higher-confidence decisions before compounds move into experimental testing. This helps computational chemists run concurrent research sessions and accomplish more across multiple programs. Press release.  

Novogene Europe expanded its single-cell RNA sequencing capability at its Cambridge Omics Centre. This expansion brings single-cell sequencing workflows built around the 10x Genomics Chromium platform closer to academic, biotech, and biopharma researchers in the U.K. The service builds on Novogene Europe’s established single-cell expertise, including existing capability in Germany, and combines specialist project support, sequencing infrastructure, and bioinformatics analysis to help researchers generate deeper biological insight from complex samples and meet growing demand for accessible single-cell transcriptomics. Press release. 

Akiram Therapeutics and ITM Isotope Technologies Munich (ITM) announced a supply agreement for non-carrier-added (n.c.a.) Lutetium-177 (Lu-177 or 177Lu) to support the development of 177Lu-AKIR001 (AKIR001), a targeted antibody-radionuclide conjugate with first-in-class potential, currently in clinical testing for the treatment of CD44v6-expressing solid tumors. Under the terms of the agreement, ITM will provide its high-quality n.c.a. Lu-177 for use in Akiram’s ongoing clinical trial for AKIR001, the company’s lead radiopharmaceutical candidate. Lu-177 is one of the most widely used medical radioisotopes in targeted radionuclide therapy and serves as the active payload in AKIR001. AKIR001 is a targeted radiopharmaceutical drug candidate that combines the therapeutic radioisotope n.c.a. Lu-177 with a proprietary antibody targeting CD44v6, a cancer marker associated with several aggressive tumor types. Press release. 

Baylor College of Medicine announced that a new research agreement with United Therapeutics Corporation will provide up to $5 million a year for five years to establish the Baylor College of Medicine Center for Xenoliver Transplantation and Immunomodulation (XTI), dedicated to advancing scientific understanding of xenoliver transplantation. XTI’s efforts will place a particular emphasis on patient populations with high unmet needs who may face additional barriers to receiving a timely liver transplant, including patients with end-stage organ failure and patients whose immune systems have formed antibodies to foreign tissue. XTI will also explore immunomodulatory interventions, including mechanisms that may drive dendritic cells, which play an important role in adaptive immune response, to improve human tolerance to a xenoliver transplantation. Press release. 

HanchorBio announced that its wholly owned Taiwan subsidiary has entered a strategic collaboration with the research team led by Professor Sung-Liang Yu of National Taiwan University, a key participating team in the Taiwan Cancer Moonshot Program. This collaboration represents an important step in HanchorBio's evolution from a clinical-stage immunotherapy company toward a precision immunotherapy platform integrating patient-derived biological insights, biomarker strategies, proprietary therapeutic engineering, and global clinical development capabilities. Press release. 

MediGuide has launched its Longevity Intelligence Service, a service designed to help individuals better understand their biological health, identify potential health risks earlier, and receive personalized clinical guidance through an integrated preventive healthcare solution that combines advanced diagnostics, predictive health intelligence, physician expertise, and coordinated care. Press release. 

The Stein Institute for Research on Aging at the University of California San Diego will serve as the Central Laboratory and Biorepository for the XPRIZE Healthspan Competition, in which teams from around the world compete for $101 million in research funding to create innovative interventions that restore muscle, cognitive, and immune function in order to extend the human healthspan. Press release. 

Owkin announced a data collaboration with Kognitic to integrate Kognitic's clinical trial data into K Pro, Owkin's AI Scientist. The collaboration will initially focus on oncology and immunology and has the potential to expand into additional therapeutic areas and datasets over time. Kognitic structures global clinical trial signals into a normalized, decision-ready evidence layer for commercial, medical, and BD teams. These signals span trial registries, pipeline timelines, and competitive landscape data. Through this collaboration, Kognitic clinical data will be accessible directly within K Pro, giving decision-making teams a single source of data across fragmented feeds. Press release. 

The COPD Foundation announced plans for an Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting for chronic obstructive pulmonary disease (COPD). This meeting is modeled after the FDA’s PFDD public meetings. The meeting will enhance understanding of how living with COPD impacts daily life experiences; capture representative perspectives across the population on what matters most for improving their condition; and inform therapy development and regulatory decision-making with insights on current care and treatment benefit needs. Press release.